Ophthalmology Times: Tepezza Receives Approval for Active Thyroid Eye Disease Treatment

Wednesday, 25 September 2024, 07:09

Ophthalmology Times highlights the approval of Tepezza for active thyroid eye disease in Japan. This breakthrough signifies a vital treatment option for patients suffering from TED. The approval marks a significant advancement in ophthalmology, especially for those with high clinical activity scores.

Amgen announced that Tepezza (teprotumumab [Genetical Recombination]) was approved by Japan's Ministry of Health, Labour and Welfare to treat active thyroid eye disease (TED) or TED with a high clinical activity score (CAS).

TEPEZZA is the first and only medicine approved in Japan to treat active TED.

An estimated 25,000 to 35,000 people in Japan have TED. This includes active and chronic (low CAS) TED. A separate phase 3 trial (jRCT2031220730) is ongoing in Japan to study the efficacy of Tepezza in patients with chronic TED and low CAS.

This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.

Related posts